Actinium soars as blood cancer therapy meets trial main goal

Actinium Pharmaceuticals

31/10/2022 11:30

** Shares of cancer therapy developer Actinium
Pharmaceuticals  ATNM.A  jump as much as ~38% to $13.39 before
the bell 
    ** ATNM says its experimental therapy, Iomab-B met, main
goal in a late-stage study testing it as a potential treatment
for a type of blood cancer  urn:newsml:reuters.com:*:nPn5lP9Lta 
    ** Co says Iomab-B showed complete remission in patients
aged 55 years or older with relapsed or refractory acute myeloid
leukemia 
    ** ATNM plans to share additional data from the late-stage
trial by year-end
    ** As of last close, ATNM up ~62% YTD
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))